A century ago, August Krogh's interest in diabetes led to the creation of insulin. Novo Nordisk developed GLP-1 analogues that evolved into successful diabetes treatments. The emergence of once-weekly formulations like Ozempic has shown remarkable weight-loss results, sparking hope and excitement among patients and healthcare providers. These medications have the potential to address the obesity epidemic by offering effective solutions for weight management.
To Another Language
from source content
www.newyorker.com
Kluczowe wnioski z
by Cond... o www.newyorker.com 12-14-2023
https://www.newyorker.com/culture/2023-in-review/the-year-of-ozempicGłębsze pytania